Raymond E - Search Results

1

Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.

Faivre S, Ronot M, Dreyer C, Serrate C, Hentic O, Bouattour M, Bruno O, Couvelard A, Vilgrain V, Raymond E. Faivre S, et al. Among authors: raymond e. Target Oncol. 2012 Jun;7(2):127-33. doi: 10.1007/s11523-012-0216-y. Epub 2012 May 15. Target Oncol. 2012. PMID: 22585430

2

Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.

Theou-Anton N, Faivre S, Dreyer C, Raymond E. Theou-Anton N, et al. Among authors: raymond e. Drug Saf. 2009;32(9):717-34. doi: 10.2165/00002018-200932090-00003. Drug Saf. 2009. PMID: 19670913 Review.

3

Sunitinib paves the way for targeted therapies in neuroendocrine tumors.

Raymond E, Faivre S, Hammel P, Ruszniewski P. Raymond E, et al. Target Oncol. 2009 Dec;4(4):253-4. doi: 10.1007/s11523-009-0130-0. Epub 2009 Nov 13. Target Oncol. 2009. PMID: 19911111

4

[Targeted therapies in hepatocellular carcinoma].

Bouattour M, Marijon H, Dreyer C, Faivre S, Raymond E. Bouattour M, et al. Among authors: raymond e. Presse Med. 2010 Jul-Aug;39(7-8):753-64. doi: 10.1016/j.lpm.2009.11.016. Epub 2010 Apr 7. Presse Med. 2010. PMID: 20378303 French.

5

Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.

Sablin MP, Dreyer C, Colichi C, Bouattour M, Delbaldo C, Faivre S, Raymond E. Sablin MP, et al. Among authors: raymond e. Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):1005-15. doi: 10.1517/17425255.2010.506872. Expert Opin Drug Metab Toxicol. 2010. PMID: 20636223 Review.

6

Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.

Faivre S, Sablin MP, Dreyer C, Raymond E. Faivre S, et al. Among authors: raymond e. Endocrinol Metab Clin North Am. 2010 Dec;39(4):811-26. doi: 10.1016/j.ecl.2010.09.006. Endocrinol Metab Clin North Am. 2010. PMID: 21095547 Review.

7

Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma.

Marijon H, Dokmak S, Paradis V, Zappa M, Bieche I, Bouattour M, Raymond E, Faivre S. Marijon H, et al. Among authors: raymond e. J Hepatol. 2011 May;54(5):1073-8. doi: 10.1016/j.jhep.2010.11.011. Epub 2010 Dec 2. J Hepatol. 2011. PMID: 21145871 Free article.

8

Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.

Faivre S, Zappa M, Vilgrain V, Boucher E, Douillard JY, Lim HY, Kim JS, Im SA, Kang YK, Bouattour M, Dokmak S, Dreyer C, Sablin MP, Serrate C, Cheng AL, Lanzalone S, Lin X, Lechuga MJ, Raymond E. Faivre S, et al. Among authors: raymond e. Clin Cancer Res. 2011 Jul 1;17(13):4504-12. doi: 10.1158/1078-0432.CCR-10-1708. Epub 2011 Apr 29. Clin Cancer Res. 2011. PMID: 21531821 Clinical Trial.

9

Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential.

Delbaldo C, Faivre S, Dreyer C, Raymond E. Delbaldo C, et al. Among authors: raymond e. Ther Adv Med Oncol. 2012 Jan;4(1):9-18. doi: 10.1177/1758834011428147. Ther Adv Med Oncol. 2012. PMID: 22229044 Free PMC article.

10

Sunitinib in pancreatic neuroendocrine tumors.

Raymond E, Hammel P, Dreyer C, Maatescu C, Hentic O, Ruszniewski P, Faivre S. Raymond E, et al. Target Oncol. 2012 Jun;7(2):117-25. doi: 10.1007/s11523-012-0220-2. Epub 2012 Jun 2. Target Oncol. 2012. PMID: 22661319 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

599 results

Search Page

Filters